Zobrazeno 1 - 10
of 60
pro vyhledávání: ''
Autor:
Kaiyang Ding, Xiao-Jun Liu, Bi-yun Chen, Qinhua Liu, Yu-Jun Dong, Juan Du, Wei Sang, Yongqiang Wei, Jing Liu, Jun Luo, Liang Zou, Juan He, Wei Wang, Wei Yang, Hongmei Jing, Jingsong He, Xinxin Cao, Zhongxing Jiang, Jian Li, Chunrui Li, Fei Li, Ou Bai, Rong Fu, Bingzong Li, Liang Wang, Zhen-Ling Li, Luoming Hua, Wenming Chen, Qi-ke Zhang, Yu Wu, Shuhua Yi, Chunyan Sun, Lugui Qiu, Lihong Liu, Xiao-Xia Chu, L. Wang, Min Mao
Publikováno v:
Leukemialymphoma. 62(11)
In this study, we aimed to investigate treatment options and the prognosis of patients with WM in China. This retrospective study included 1141 patients diagnosed with symptomatic WM between January 2003 and December 2019 at 35 tertiary hospitals in
Autor:
Louis M. Staudt, Amy S. Kimball, Sven de Vos, Jerry Ping, Darrin M. Beaupre, Wyndham H. Wilson, Da-Wei Huang, Kevin A. Kwei, George E. Wright, Leslie Popplewell, Jutta K. Neuenburg, Saurabh Chhabra, Tycel Phillips
Publikováno v:
Leukemialymphoma. 62(9)
Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) is difficult to cure; non-germinal center B-cell-like (non-GCB) and activated B-cell-like (ABC) DLBCL have worse outcomes than GCB DLBCL. Ibrutinib and lenalidomide are synergistic in vitro in
Autor:
M Gyger, Lisa W. Le, Zhihua Li, Richard Leblanc, Suzanne Trudel, Darrell White, Harminder Paul, Johnathan Kaufman, Engin Gul, Sahar Khan, Andrzej Jazubowiak, Anthea Lau
Publikováno v:
Leukemialymphoma. 62(7)
We report results of a phase-1 study evaluating the safety and anti-cancer activity of the small molecule insulin-like growth factor-1 receptor (IGF-1R) inhibitor, linsitinib combined with bortezomib, and dexamethasone in relapsed/refractory multiple
Autor:
Ganesh Kumar Vishwanathan, Jasmita Dass, Rishi Dhawan, Pradeep Kumar, Mukul Aggarwal, Tulika Seth, Manoranjan Mahapatra, Seema Tyagi, Jayastu Senapati
Publikováno v:
Leukemialymphoma. 62(6)
Despite improvements in leukemia therapy, acute myeloid leukemia (AML) remain a difficult disease to treat with a majority of patients having disease relapse without an allogeneic stem cell transpl...
Autor:
Rakesh Popat, Jonathan Sive, Xenofon Papanikolaou, Shameem Mahmood, Gabrielle Lawson, Sajitha Sachchithananthan, Neil Rabin, Simon Cheesman, Kwee Yong, Dunnya De-Silva, Charalampia Kyriakou, Monica Ziff, Ashutosh D. Wechalekar
Publikováno v:
Leukemialymphoma. 62(5)
A number of new treatments have been approved for patients with multiple myeloma (MM) and the survival of patients continues to improve. However, discrepancies in outcomes of clinical trials and th...
Autor:
Prithviraj Bose, Guillermo Garcia-Manero, Wen Wan, John D. Roberts, Sandeep S. Dave, Elizabeth B. Collins, Steven Grant, Ellen Shrader, Victor Yazbeck, Caryn Weir, Dipankar Bandyopadhyay, Maciej Kmieciak, Amanda Garnett, Danielle Shafer, Mary Beth Tombes, Beata Holkova
Publikováno v:
Leuk Lymphoma
We report the results of a phase 1 dose-escalation study of belinostat and bortezomib in adult patients with acute leukemia or MDS or CML with blast crisis. Thirty-eight patients received IV belinostat days 1-5 and 8-12 with IV bortezomib days 1, 4,
Autor:
Grant Vallance, Bhuvan Kishore, Rebecca Robinson, Kevin Boyd, Moez Dungarwalla, Gurvin Chander, Karthik Ramasamy, Robin Aitchison, Matthew W Jenner, Jaimal Kothari, Sarah Bird, Zara Bhatti, Freya Collings, Nadjoua Maouche, Andy Peniket, Mark Offer, Ceri Bygrave
Publikováno v:
Leukemialymphoma. 62(6)
There are limited real world data on ixazomib, lenalidomide, and dexamethasone (IRd) in multiply relapsed myeloma. We analyzed outcomes of 116 patients who received IRd predominantly at second and subsequent relapse including those refractory to prot
Autor:
John M. Burke, Michael Boxer, Habte A. Yimer, Gibb study investigators, Sunil Babu, Yeung-Chul Mun, Jeff P. Sharman, Alexey V. Danilov, Jia Li
Publikováno v:
Leukemialymphoma. 62(4)
The single-arm, multicenter, phase 2 GIBB study (NCT02320487) investigated bendamustine plus obinutuzumab (BG) in previously untreated CLL. Patients (N = 102) received six cycles of intravenous obi...
Autor:
Krystal Bergin, Malarmathy Ramachandran, Antonia Reale, John V. Reynolds, Roberto Ria, Maoshan Chen, Andrew Spencer, Tiffany Khong, Jay Hocking, Sridurga Mithraprabhu, Francesco Silvestris, Angelo Vacca, Ioanna Savvidou, F. Dammacco
Publikováno v:
Leukemialymphoma. 62(2)
Microarray was utilized to determine if a genetic signature associated with resistance to carfilzomib (CFZ) could be identified. Twelve human myeloma (MM) cell lines (HMCLs) were treated with CFZ and a cell-viability profile was assessed categorizing
Autor:
Kazutoshi Ebisawa, Akira Honda, Arika Shimura, Fumio Nakahara, Mineo Kurokawa, Yosuke Masamoto
Publikováno v:
Leukemialymphoma. 62(3)
Although anti-interleukin-6 therapy with tocilizumab and siltuximab is recommended for multicentric Castleman's disease (MCD), burdens caused by frequent hospital visits and high drug payments is an issue to be considered. Although glucocorticoid mon